Celator Pharmaceuticals Inc. (Nasdaq: CPXX) reported positive induction
response rates in a Phase 3 study of CPX-351 liposome injection to treat
patients with high-risk acute myeloid leukemia. The stock price gained 53 cents to close at $2.77.
Positive study results for Celator Pharmaceuticals
June 24, 2015 at 17:07 PM EDT
